Change in patient‐reported symptom scores (lower is favored) · people with dry eye
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Proportion of participants with intervention‐related, vision‐threatening adverse events at 1 to 4 weeks · people with dry eye
1 finding from 1 review
Mean change from baseline in meibomian gland expression scores at 1 to 4 weeks (higher is favored) · people with dry eye
It is very uncertain whether lipiFlow changes mean change from baseline in meibomian gland expression scores at 1… compared with basic warm compresses (very low certainty).
1 finding from 1 review
Mean change from baseline in meibum quality scores at 1 to 4 weeks (higher is favored) · people with dry eye
It is very uncertain whether lipiFlow changes mean change from baseline in meibum quality scores at 1 to 4 weeks… compared with basic warm compresses (very low certainty).
1 finding from 1 review
Mean change from baseline in meibomian gland atrophy scores at 1 to 4 weeks (lower is favored) · people with dry eye
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Proportion of participants with intervention‐related, vision‐threatening adverse events at 1 to 4 weeks · people with dry eye
1 finding from 1 review
Change in patient‐reported symptom scores (lower is favored) · people with dry eye
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Mean change from baseline in meibomian gland expression scores at 1 to 4 weeks (higher is favored) · people with dry eye
LipiFlow showed no clear difference in mean change from baseline in meibomian gland expression scores at 1… compared with thermostatic devices (low certainty).
1 finding from 1 review
Mean change from baseline in meibum quality scores at 1 to 4 weeks (higher is favored) · people with dry eye
LipiFlow showed no clear difference in mean change from baseline in meibum quality scores at 1 to 4 weeks… compared with thermostatic devices (low certainty).
1 finding from 1 review
Mean change from baseline in meibomian gland atrophy scores at 1 to 4 weeks (lower is favored) · people with dry eye
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Proportion of eyes with retinal displacement at 6 months or later (RR < 1 favored) · people with primary macula‐involving rhegmatogenous retinal detachments
It is very uncertain whether face‐down positioning changes proportion of eyes with retinal displacement at 6 months or later… compared with other positioning (very low certainty).
1 finding from 1 review
Visual acuity · people with primary macula‐involving rhegmatogenous retinal detachments
It is very uncertain whether face‐down positioning changes mean change in logMAR or Snellen visual acuity from baseline to 3… compared with other positioning (very low certainty).
1 finding from 1 review
Mean objective distortion score at 3 months or later (lower is favored) · people with primary macula‐involving rhegmatogenous retinal detachments
It is very uncertain whether face‐down positioning changes mean objective distortion score at 3 months or later (lower is… compared with other positioning (very low certainty).
1 finding from 1 review
Quality of life assessments at 3 months or later (higher is favored) · people with primary macula‐involving rhegmatogenous retinal detachments
It is very uncertain whether face‐down positioning changes quality of life assessments at 3 months or later (higher is favored) compared with other positioning (very low certainty).
1 finding from 1 review
Frequency of intervention‐related ocular adverse events ( · people with primary macula‐involving rhegmatogenous retinal detachments
1 finding from 1 review
Frequency of intervention‐related non‐ocular adverse events ( · people with primary macula‐involving rhegmatogenous retinal detachments
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Progression to late AMD (neovascular AMD, geographic atrophy or both) · people with AMD
Antioxidant multivitamin and mineral supplement probably leads to lower progression to late AMD (neovascular AMD, geographic atrophy, or both) compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Progression to geographic atrophy · people with AMD
Lutein with or without zeaxanthin showed no clear difference in progression to geographic atrophy compared with placebo (low certainty).
1 finding from 1 review
Progression to visual loss (loss of 3 or more lines on logMAR chart) · people with AMD
Lutein with or without zeaxanthin showed no clear difference in progression to visual loss (loss of 3 or more lines on logMAR chart) compared with placebo (low certainty).
1 finding from 1 review
Quality of life · people with AMD
1 finding from 1 review